Xenon Pharmaceuticals' (XENE) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. Cantor Fitzgerald currently has a $58.00 price target on the biopharmaceutical company’s stock. XENE has been the topic of several other research reports. Stifel Nicolaus lifted their price target […]

Related Keywords

California ,United States ,Canada ,Arizona ,Simonn Pimstone ,Stifel Nicolaus ,Xenon Pharmaceuticals ,Needham Company ,Jpmorgan Chase Co ,Analyst Recommendations For Xenon Pharmaceuticals ,Securities Exchange Commission ,News Ratings For Xenon Pharmaceuticals Daily ,Xenon Pharmaceuticals Inc ,Cantor Fitzgerald ,Stifel Financial Corp ,Xenon Pharmaceuticals Trading Down ,Free Report ,Moderate Buy ,Pharmaceuticals Trading Down ,Get Free Report ,Director Simon ,Exchange Commission ,Director Dawn Svoronos ,State Teachers Retirement System ,Financial Corp ,Arizona State Retirement System ,State Retirement System ,Pharmaceuticals Inc ,Xenon Pharmaceuticals Daily ,Nasdaq Xene ,Exene ,Medical ,Reiterated Rating ,